Streptokinase Abstract

A chance discovery by William Smith Tillett 1933, followed by many years of work with Sol Sherry students has laid a solid foundation for the use of streptokinase as thrombolytic agents in the treatment of acute myocardial infarction. Drugs found first clinical application in the control of fibrinous pleural effusion, hemothorax and tuberculous meningitis. In 1958, Sherry and others began streptokinase in patients with acute myocardial infarction with and changed the bleaching treatment center "cure" for. The first attempts to streptokinase infusion contradictory results used. An innovative approach to intracoronary streptokinase infusion was 1979 and larger intracoronary infusion studies have achieved patency rates of 70% to 90% of Rentrop and his colleagues began. The need for a multicenter randomized systematic and carefully planned was conducted filled by the sperimentazione della streptokinase dell'Infarto Miocardico Gruppo Italiano per study (GISSI) in 1986, which not only valid streptokinase as an effective therapeutic method, but also established a solid record for use in acute myocardial infarction. Currently, despite the widespread use of tissue plasminogen activator, streptokinase in industrialized countries remains essential for the treatment of acute myocardial infarction in developing countries.